[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354350-105":59,"doc-detail-354350-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","understanding-and-overcoming-innate-and-acquired-mapk-inhibition-resistance-in-anaplastic-thyroid-cancer","Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer","","Anaplastic thyroid cancer (ATC) is highly lethal, with patients often developing adaptive or acquired resistance after initial response to dabrafenib plus trametinib targeting BRAFV600E. By applying translational genomics and patient-derived models, Zeng and colleagues map how MAPK pathway reactivation and immunosuppressive macrophage proliferation contribute to resistance under type I RAF/MEK inhibition. They further show naporafenib with trametinib overcomes both innate and acquired resistance, while compensatory MAST1 mutations mediate resistance to naporafenib.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/understanding-and-overcoming-innate-and-acquired-mapk-inhibition-resistance-in-anaplastic-thyroid-cancer/354350/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/understanding-and-overcoming-innate-and-acquired-mapk-inhibition-resistance-in-anaplastic-thyroid-cancer/354350.png","ImageObject",300,407,{"name":92,"@type":93},"4398046744996","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is resistance common in anaplastic thyroid cancer treated with type I RAF inhibitors plus MEK inhibitors?","Question",{"text":112,"@type":113},"Most patients rapidly develop adaptive or acquired resistance. Reactivation of the MAPK pathway together with immunosuppressive macrophage proliferation is linked to the development of acquired resistance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do naporafenib and trametinib affect sensitivity in ATC models?",{"text":117,"@type":113},"The study reports that ATC cell lines are highly sensitive to the type II RAF inhibitor naporafenib. In combination with trametinib, it overcomes both innate and acquired resistance to dabrafenib and trametinib.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism drives acquired resistance to naporafenib?",{"text":121,"@type":113},"Acquired resistance to naporafenib occurs through compensatory MAST1 mutations, which enable continued signaling despite type II RAF inhibition.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354350,1790322448,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":66,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":133,"file_id":134,"file_url":135,"file_type":136,"file_size":137,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":138,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":139,"faqs":140,"seo_title":141,"seo_description":67,"update_tm":142,"read_time":31,"preview_page_count":19,"preview_urls":143},4398046744996,"Article  \nUnderstanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer  \nAuthors  \nPeter Y.F. Zeng, Jalna Meens,  \nAmir Hossein Karimi,   , Paul C. Boutros, Laurie Ailles, Anthony C. Nichols  \nCorrespondence  \n[laurie.ailles@uhn.ca](laurie.ailles@uhn.ca) (L.A.),  \n[anthony.nichols@lhsc.on.ca](anthony.nichols@lhsc.on.ca) (A.C.N.)  \nIn brief  \nUsing translational genomics and patientderived models, Zeng et al. find that naporafenib and trametinib overcome resistance to clinically approved RAF/ MEK inhibitors in anaplastic thyroid cancer. Further, acquired resistance tonaporafenib occurs through compensatory MAST1 mutations. This work provides a rationale for clinical investigation of type II RAF inhibitors in ATC.  \n• The combination overcomes innate and acquired resistance to type I RAF inhibitors  \n• MAST1 mutations drive acquired resistance to naporafeniband trametinib in ATC  \nZeng et al., 2026, Cell Reports Medicine 7, 102820  \nJune 16, 2026 © 2026 The Authors. Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2026.102820](https://doi.org/10.1016/j.xcrm.2026.102820)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nUnderstanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer  \nPeter Y. F. Zeng,1,2 Jalna Meens,3,4 Amir Hossein Karimi,1,2 Harrison Pan,1,2 Matthew J. Cecchini,2,5 Laura Jarycki,1 Sarah B. Ryan,1 Alice E. Dawson,1 Mushfiq H. Shaikh,1,13 David A. Palma,5 Eric Winquist,5 Lakshman Gunaratnam,6,7 Joe S. Mymryk,1,5,6 John W. Barrett,1 Paul C. Boutros,8,9,10,11,12 Laurie Ailles,3,4,* and Anthony C. Nichols1,5,14,*  \n1Department of Otolaryngology – Head & Neck Surgery, Western University, London, ON, Canada  \n2Department of Pathology and Laboratory Medicine, Western University, London, ON, Canada  \n3Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada  \n4Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1L7, Canada  \n5Department of Oncology, Western University, London, ON, Canada  \n6Department of Microbiology & Immunology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada  \n7Matthew Mailing Centre for Translational Transplant Studies, London Health Sciences Centre Research Institute, London Health Sciences Centre, London, ON, Canada  \n8Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA  \n9Department of Urology, University of California, Los Angeles, Los Angeles, CA, USA  \n10Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA, USA  \n11Institute for Precision Health, University of California, Los Angeles, Los Angeles, CA, USA  \n12Jonsson Comprehensive Cancer Centre, University of California, Los Angeles, Los Angeles, CA, USA  \n13Present address: School of Medicine, University of Texas Rio Grande Valley, Edinburg, TX, USA  \n14Lead contact  \n*Correspondence: [laurie.ailles@uhn.ca](laurie.ailles@uhn.ca) (L.A.), [anthony.nichols@lhsc.on.ca](anthony.nichols@lhsc.on.ca) (A.C. N.) [https://doi.org/10.1016/j.xcrm.2026.102820](https://doi.org/10.1016/j.xcrm.2026.102820)  \nSUMMARY  \nAnaplastic thyroid cancer (ATC) is highly lethal. Although patients with the BRAFV600E alteration respond to the type I RAF inhibitor (RAFi) dabrafenib with trametinib, most rapidly develop adaptive or acquired resistance. Here, multi-region whole-genome, high-coverage whole-exome, and single-nuclei RNA sequencing of tumors from ATC patients undergoing type I RAFi and MEKi therapy reveals that reactivation of the mitogen-activated protein kinase (MAPK) pathway, along with immunosuppressive macrophage proliferation, may underlie the development of acquired resistance. Screening of several RAFi reveals that ATC cell lines are exquisitely sensitive to the type II RAFi naporafenib, which inhibits EphA2-mediated MAPK signaling. Further, naporafenib and trametinib overcome both","cbCaipIRVmssHmmR","https://ap.wps.com/l/cbCaipIRVmssHmmR","pdf",6788197,"English","# Summary\n# Introduction\n## MAPK-RAS pathway prevalence in cancers\n## BRAFV600E and tissue-specific resistance in thyroid cancers\n# Mechanisms of innate and acquired resistance","[{\"question\":\"Why is resistance common in anaplastic thyroid cancer treated with type I RAF inhibitors plus MEK inhibitors?\",\"answer\":\"Most patients rapidly develop adaptive or acquired resistance. Reactivation of the MAPK pathway together with immunosuppressive macrophage proliferation is linked to the development of acquired resistance.\"},{\"question\":\"How do naporafenib and trametinib affect sensitivity in ATC models?\",\"answer\":\"The study reports that ATC cell lines are highly sensitive to the type II RAF inhibitor naporafenib. In combination with trametinib, it overcomes both innate and acquired resistance to dabrafenib and trametinib.\"},{\"question\":\"What mechanism drives acquired resistance to naporafenib?\",\"answer\":\"Acquired resistance to naporafenib occurs through compensatory MAST1 mutations, which enable continued signaling despite type II RAF inhibition.\"}]","Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer | PDF",1790110231,[144,148,152,156],{"page_no":8,"url":145,"width":146,"height":147},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a747bf43c6264c07d9fa3359504076a6.webp",983,1276,{"page_no":14,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc7d14eff84eac5cdec9588e0a3c6bec.webp",982,1275,{"page_no":81,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/05ee885429f2df7aff4d60290c4e7cb3.webp",981,1273,{"page_no":19,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf153eb26cc8cfa4af376adc8046d572.webp",980,1272]